Nivolumab,Ipilimumab
BMS
['lung', 'nivolumab', 'nivo', 'nsclc', 'sclc']
neoadjuvant treatment with nivolumab plus chemotherapy yielded improvements in outcomes vs chemotherapy alone in patients with resectable non small cell lung cancer undergoing definitive surgery. #nsclc #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.